Novo Nordisk’s new obesity drug led to statistically significant weight loss and blood sugar improvements in people with diabetes, a trial has found, in a positive sign for the Danish company’s treatment pipeline.
Patients with type 2 diabetes using amycretin lost up to 14.5 per cent of their body weight, compared with 2.6 per cent for those on a placebo. The drug also reduced blood sugar levels, with about 90 per cent of participants in the stage 2 trial reporting blood glucose levels below 7 per cent. The normal range is below 6 per cent.
The new drug combines semaglutide, the active ingredient in Novo’s diabetes and obesity blockbusters Ozempic and Wegovy, with amylin, a hormone that promotes a feeling of fullness.
您已阅读30%（725字），剩余70%（1690字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。